DAJY(002030)2023-11-01 12:38Group 1: Company Overview and Financials - The company raised 160 million yuan during its IPO and has not pursued further financing or corporate bond issuance since then [2] - The company relies on self-sustained growth through scale production and continuous product innovation [2] Group 2: Market Adaptation and Policy Response - The introduction of the price negotiation and procurement policy is beneficial for innovative large-scale IVD companies, testing their adaptability to new market rules [1] - Product pricing will be influenced by national policies and market competition, with the company closely monitoring these factors [2] Group 3: Product Development and Export Strategy - The company has exported PCR products to over 140 countries, indicating a strong international presence and capacity [2] - The company is focusing on expanding its product line in the field of chemiluminescence and has entered the full IVD domain, emphasizing diagnostic technology and products [3] Group 4: Future Directions - The company aims to strengthen its position in PCR and molecular diagnostics while actively developing immunology, biochemistry, and analytical instruments [3] - The company is committed to becoming a "IVD World Factory" with a complete product chain and high cost-performance products [2]